Custom service

Epitope Mapping

Where the antibody binds, at peptide or at residue resolution.

Methods: Peptide scan, HDX-MS — mutagenesis, binningResolution: Residue-level — with HDX-MS and crystallographyTimeline: 3–8 weeks — depending on method

Two antibodies that bind the same antigen can behave completely differently in an assay, and the difference is usually the epitope. A pair that competes cannot form a sandwich; a binder that recognises a linear sequence survives denaturation while a conformational binder does not; and a therapeutic candidate that blocks the ligand-binding site is a different molecule from one that binds the opposite face. Epitope mapping converts those observations into a defined answer.

Method choice follows from the question and from the available material. Overlapping peptide scanning — 15-mers offset by three to five residues, synthesised on membranes or in plates — resolves linear epitopes quickly and cheaply. Alanine scanning mutagenesis of the antigen identifies residues that contribute to binding energy. Hydrogen–deuterium exchange mass spectrometry works on the folded protein and reports conformational epitopes without mutagenesis. Competition binning is faster still and answers the practical question of whether two antibodies can pair.

Resolution and cost scale together. Binning answers 'can these pair' in a week; peptide scanning answers 'which sequence' in three; HDX-MS and crystallography answer 'which residues, in which conformation' in six to twelve weeks. Most projects need the first two, and only therapeutic or intellectual-property work justifies the third.

Service Highlights

Where it fits

Epitope mapping is essential when selecting a sandwich pair, when characterising a neutralising antibody, when explaining cross-reactivity or its absence, and when a patent or a regulatory dossier requires a defined binding site.

It is unnecessary for routine reagent development, where binding to the antigen is sufficient. It is also unreliable when applied to polyclonals, which bind many epitopes simultaneously and cannot be mapped as a single site.

Documentation and QC

Reports include the full peptide or mutant panel with raw signals, the criteria used to call a residue part of the epitope, and a statement of confidence. Where peptide scanning is negative, we say so explicitly and recommend HDX-MS rather than reporting an empty map.

Frequently asked questions

My antibody does not bind any peptide. Does that mean it has no epitope?

No. It usually means the epitope is conformational. Peptide scanning only detects linear epitopes; a negative result should be followed by HDX-MS or by mutagenesis on the folded protein.

How accurate is peptide scanning?

It localises a linear epitope to roughly a five-residue window reliably, but it can produce false positives from peptides that adsorb non-specifically. Every hit is confirmed by alanine substitution before being reported.

Can you map two antibodies at once to find a pair?

Yes. Competition binning in a BLI format tests each pair directly, and it is the fastest route to a working sandwich assay — usually a week rather than a month.

Tell us whether the question is pairing, blocking or intellectual property. The method follows from that, and the cheapest one that answers it is the one we will propose.

Service Highlights

  • Method matched to the question. Binning for pairing, peptide scanning for linear epitopes, HDX-MS for conformational ones, and mutagenesis to confirm.
  • Overlapping peptide arrays. 15-mer peptides with 3–5 residue offsets, covering the full sequence, with a scrambled control for each.
  • Alanine scanning. Systematic substitution of surface residues, expressed and tested individually to locate contact points.
  • HDX-MS without mutagenesis. Protection patterns compared between antibody-bound and free antigen, resolved to peptide-level segments.
  • Competition binning. Pairwise BLI or SPR to define bins and to identify non-competing pairs for sandwich assays.
  • Cross-reactivity explained. Homologue comparison shows whether a non-binding result is due to a single residue difference.

How the work runs

  1. Sequence and structure review

    The antigen sequence, known domains and available structures are assessed to choose the method and to predict whether the epitope is likely linear or conformational.

  2. Peptide library design

    Peptides covering the full sequence with defined overlaps, plus truncated and alanine-substituted variants where a fine map is needed.

  3. Binding assay

    ELISA or membrane-based probing of the peptide library, with the parent protein and a scrambled peptide as controls, run in duplicate.

  4. Mutagenesis confirmation

    Selected residues substituted to alanine, expressed recombinantly, and tested to confirm that binding loss is due to the substitution rather than to misfolding.

  5. Conformational analysis

    HDX-MS or competition binning for antibodies that do not bind peptides, since a negative peptide result is not evidence of no epitope.

  6. Reporting

    Epitope residues mapped onto the sequence and, where a structure exists, onto the surface, with the confidence level stated.

Specifications & timeline

Methods
Peptide scan, HDX-MS — mutagenesis, binning
Resolution
Residue-level — with HDX-MS and crystallography
Timeline
3–8 weeks — depending on method
Peptide scanning
15-mer with 3-residue offset, full sequence coverage, ELISA or membrane format
Mutagenesis
Alanine scanning of surface residues, 10–40 variants per antigen
HDX-MS
Peptide-level resolution, 85–95% sequence coverage typical
Binning
Pairwise BLI or SPR, output as a bin matrix
Timeline
1 week for binning, 3 weeks for peptide scanning, 6–8 weeks for HDX-MS
Deliverables
Epitope map, raw binding data, structural model where available, bin matrix

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.